About Salus IRB

About Salus IRB

Salus IRB board members are qualified, knowledgeable experts, many with years of experience as investigators conducting clinical trials. Our boards are appropriately diverse, satisfying the requirements of 21 CFR 56.107 and 45 CFR 46.107.

Salus boards include physicians, pharmacists, doctors of pharmacy, ethics attorneys, toxicologists, radiation safety officers and nurses (including pediatric and oncology), as well as lay community members who do not have scientific or medical backgrounds. Salus board members have industry experience in drug safety, drug development, regulatory and medical affairs, protocol development and monitoring, research science, patient/research participant advocacy, and working with vulnerable populations. The boards may utilize a special consultant to assist in the review of a protocol requiring additional expertise to supplement that of the board.

The boards review phase I-IV research, post-marketing surveillance, drug, device, social/behavioral, educational methods, first-in-man, adaptive protocol designs, phase I oncology, companion diagnostics, human factors and usability studies, investigator-initiated research, innovative research, decentralized trials, and outcomes research in a variety of therapeutic areas in the pharmaceutical, biotech and medical device industries, including but not limited to:

  • Allergy
  • Cardiology
  • Dermatology
  • Endocrinology
  • Gastroenterology
  • General Internal Medicine
  • General Practice
  • Hypertension
  • Immunology
  • Infectious Disease
  • Nephrology
  • Oncology
  • Ophthalmology
  • Pharmacy
  • Psychiatry
  • Respiratory
  • Rheumatology
  • Toxicology
  • Urology
 
Benefits include:
  • Responsive administrative points of contact
  • Streamlined document submission and delivery process
  • Industry-leading review and response times
  • IRB meetings held every Monday, Tuesday, Wednesday and Friday
  • Comprehensive review services for phase I-IV research
  • Experience in toxicology and accelerated phase I review services
  • Dedicated oncology board with experience reviewing oncology research, including phase I
  • Single IRB/central IRB services for multi-site trials


 
Nichole Miller

Organizational Official

Read Bio
 
Marilyn Eshikena

Director of IRB Operations and Compliance

Read Bio
 
Leslie Wilson

Director of Client Services

Read Bio
 
Meli Salinas

Manager, Board Services

Read Bio
 
Trina Anderson

QA & Compliance Manager

Read Bio

Salus IRB Mission & Values

Explore Salus IRB's mission and values: committed to ethical research, participant protection, and advancing knowledge with integrity and respect.

 

Compliance Statement

Salus IRB is appropriately constituted, organized and conducts ethical review in accordance with the U.S. Food and Drug Administration 21 CFR Parts 50 and 56, the Department of Health and Human Services 45 CFR Part 46, and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice E6(R2).

Salus IRB is registered with the United States Department of Health and Human Services (DHHS) IRB Registration System for OHRP and FDA under parent organization number IORG0005674 and registration numbers IRB00006833 (Board 1), IRB00006834 (Board 2), IRB00009473 (Board 3), IRB00013027 (Board 4), and IRB00013544 (Board 5).

Salus IRB has been fully accredited since 2009 by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP).

 
Partner with Salus IRB
Contact Salus IRB for assistance with research ethics, compliance, and protocol submissions. Find contact details and resources to support your research needs.
Learn More
 
Salus IRB Services
Institutional review board Salus IRB provides single-site, multi-site (single IRB/central IRB), and international review services for clinical trials.
Learn More
 
Meet the Salus IRB Leadership Team
Meet the Salus IRB leadership team: dedicated experts guiding ethical research, participant safety, and compliance with the highest standards of integrity.
Learn More